Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
33.72
-0.39 (-1.14%)
Jan 29, 2026, 10:55 AM EST - Market open
Axogen Revenue
Axogen had revenue of $60.08M in the quarter ending September 30, 2025, with 23.51% growth. This brings the company's revenue in the last twelve months to $214.71M, up 18.72% year-over-year. In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth.
Revenue (ttm)
$214.71M
Revenue Growth
+18.72%
P/S Ratio
7.30
Revenue / Employee
$475,020
Employees
452
Market Cap
1.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | 106.71M | 22.78M | 27.13% |
| Dec 31, 2018 | 83.94M | 23.51M | 38.91% |
| Dec 31, 2017 | 60.43M | 19.32M | 46.99% |
| Dec 31, 2016 | 41.11M | 13.78M | 50.41% |
| Dec 31, 2015 | 27.33M | 10.51M | 62.52% |
| Dec 31, 2014 | 16.82M | 5.87M | 53.62% |
| Dec 31, 2013 | 10.95M | 3.26M | 42.33% |
| Dec 31, 2012 | 7.69M | 2.84M | 58.61% |
| Dec 31, 2011 | 4.85M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.26B |
| QuidelOrtho | 2.71B |
| Enovis | 2.23B |
| Tandem Diabetes Care | 1.01B |
| Alphatec Holdings | 728.02M |
| NovoCure | 642.27M |
| UFP Technologies | 597.95M |
| Artivion | 422.65M |
AXGN News
- 7 days ago - Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock - GlobeNewsWire
- 7 days ago - Axogen Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 - GlobeNewsWire
- 2 months ago - Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) - GlobeNewsWire
- 2 months ago - FDA approves Axogen's nerve repair graft - Reuters
- 2 months ago - Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen - Seeking Alpha
- 3 months ago - Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors - Seeking Alpha